Boston gets back on track as Irish plant in the clear
This article was originally published in Clinica
Following a seven-day US FDA inspection of Boston Scientific's Galway, Ireland-based factory, the agency has reported that no observations were made at the facility where the company's Taxus Express2 drug-eluting stent (DES) is manufactured. The inspection was carried out as part of the ongoing investigation into the worldwide recall of nearly 100,000 Taxus DESs throughout July and August. The FDA has already given Boston's other DES plant in Maple Grove, Minnesota the all-clear when it inspected the facility in July.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.